BioSpace News Archive

QYNAPSE Inc. is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28-30, 2021, to present the latest advances in its solutions, which are transforming clinical care and clinical trials for patients with brain disorders, such as Alzheimer’s, Parkinson’s and Multiple Sclerosis.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists Annual Meeting 2021.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced the appointment of Errol De Souza, Ph.D., to its board of directors.

Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Jean-Philippe Pignol , M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021 .

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company’s Scientific Advisory Board, effective April 26, 2021.

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Vicki Vakiener to its Board of Directors, effective immediately.

Patients Administered ANJESO Prior to the Start of Surgery had Significantly Lower Summed Pain Intensity Scores on the First Postsurgical Day and Throughout Their Inpatient Course

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it will release its first quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, May 6, 2021.

Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, announced today that the U.S. Food and Drug Administration (FDA) granted De Novo market authorization for its groundbreaking IpsiHand Upper Extremity Rehabilitation System.

X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.